Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.85 USD | +0.88% | -5.32% | +0.35% |
May. 09 | Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 | |
Apr. 17 | DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 147M 107M |
---|---|---|---|---|---|
Net income 2024 * | -36M -26.22M | Net income 2025 * | -47M -34.23M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.07
x | P/E ratio 2025 * |
-3.28
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.96% |
Latest transcript on DiaMedica Therapeutics Inc.
1 day | +0.88% | ||
1 week | -5.32% | ||
Current month | +12.65% | ||
1 month | +13.55% | ||
3 months | -0.70% | ||
6 months | +10.03% | ||
Current year | +0.35% |
Managers | Title | Age | Since |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 05-03-31 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 18-03-31 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 23-05-29 |
Tanya Lewis
BRD | Director/Board Member | 53 | 23-02-28 |
James Parsons
BRD | Director/Board Member | 58 | 10-10-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 2.85 | +0.88% | 19,658 |
24-05-22 | 2.825 | -7.07% | 18,494 |
24-05-21 | 3.04 | -0.65% | 7,788 |
24-05-20 | 3.06 | -3.47% | 6,661 |
24-05-17 | 3.17 | 0.00% | 7,101 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.35% | 107M | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- DMAC Stock